Literature DB >> 6698991

Albumin-eicosanoid interactions. A model system to determine their attributes and inhibition.

F A Fitzpatrick, W F Liggett, M A Wynalda.   

Abstract

A model system was developed to (a) reflect the chemical attributes of the microenvironment involved in albumin-eicosanoid interactions and (b) determine the effects of other ligands on these interactions. Albumin-dependent modulation of prostaglandin stability was chosen as the basis for this system. 15-Ketoprostaglandin E2 (PGE2) was evaluated as a model ligand because under special conditions it decomposes with formation of a visible chromophore. Human serum albumin, in a concentration-dependent fashion, catalyzed the dehydration of 15-keto-PGE2 with the concurrent generation of this chromophore (lambda max = 505 nm, epsilon = 35,000). Since chromophore production from 15-keto-PGE2 in albumin-free solution occurs only at pH greater than 10, the results suggest that albumin-eicosanoid interactions involve a microenvironment with alkaline attributes. The effect of other ligands on albumin-15-keto-prostaglandin E2 interactions was determined by monitoring their ability to inhibit the spectral component of these interactions. Inhibition correlated with an affinity for specific binding sites on albumin. At mole ratios of ligand/albumin below 1, only phenylbutazone, its analogs, and warfarin inhibited chromophore development. Other ligands including fatty acids, steroids, tryptophan, and drugs with an affinity for other binding sites were ineffective inhibitors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6698991

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Structural insights into human serum albumin-mediated prostaglandin catalysis.

Authors:  Jinsheng Yang; Charles E Petersen; Chung-Eun Ha; Nadhipuram V Bhagavan
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  Human group II 14 kDa phospholipase A2 activates human platelets.

Authors:  J Polgár; R M Kramer; S L Um; J A Jakubowski; K J Clemetson
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

3.  New site(s) of methylglyoxal-modified human serum albumin, identified by multiple reaction monitoring, alter warfarin binding and prostaglandin metabolism.

Authors:  Michael J Kimzey; Hussein N Yassine; Brent M Riepel; George Tsaprailis; Terrence J Monks; Serrine S Lau
Journal:  Chem Biol Interact       Date:  2010-10-08       Impact factor: 5.192

4.  Characterization of prostaglandin E2 production by Candida albicans.

Authors:  John R Erb-Downward; Mairi C Noverr
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

Review 5.  Leukotrienes in pulmonary arterial hypertension.

Authors:  Wen Tian; Xinguo Jiang; Yon K Sung; Jin Qian; Ke Yuan; Mark R Nicolls
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

6.  Blood plasma influences anti-aggregatory potency of prostaglandins: effect of albumin.

Authors:  G Kobzar; V Mardla; I Järving; N Samel
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

7.  Toxicity of allelopathic monoterpene suspensions on yeast dependence on droplet size.

Authors:  S Uribe; A Pena
Journal:  J Chem Ecol       Date:  1990-04       Impact factor: 2.626

8.  Immunohistochemical distribution of serum proteins in living mouse heart with In vivo cryotechnique.

Authors:  Liye Shi; Nobuo Terada; Yurika Saitoh; Sei Saitoh; Shinichi Ohno
Journal:  Acta Histochem Cytochem       Date:  2011-03-29       Impact factor: 1.938

9.  Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated.

Authors:  Werner I Hagens; Adriana Mattos; Rick Greupink; Alie de Jager-Krikken; Catharina Reker-Smit; Annemiek van Loenen-Weemaes; I Annette S H Gouw; Klaas Poelstra; Leonie Beljaars
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.